QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in Phase 2 MS1819-PERT Combination Clinical Trial
AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases,…